UIG News
About UIG
References
UIG Services
Contact Us
Samsung Bioepis wins FDA approval for rheumatoid arthritis drug that competes with Johnson & Johnson
Samsung Bioepis has won U.S. regulatory approval for key biosimilar drug.
«
IMF torn over whether to bail ...
Pence says United States will ...
»